Spike Protein News and Research

RSS

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Researchers from the US recently characterized the scale and specificity of SARS-CoV-2 spike-reactive antibodies from 23 participants who received SARS-CoV-2 mRNA vaccines and 10 acutely infected health care workers. They found that primary mRNA vaccination and infection elicited S1- and S2-reactive antibodies, while secondary mRNA vaccination elicited mostly S1 antibodies.

4 Oct 2021

Fully vaccinated people with prior SARS-CoV-2 infection have more memory B cells, study shows

A new study by University of Minnesota Medical School researchers is revealing that some people who received an mRNA vaccination for COVID-19 have greater immune responses compared to others.

4 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

A new study used the available nucleotide sequence data on the NCBI COVID-19 database and estimated the global prevalence of adaptive and prolonged infections' mutations in the RBD of the S protein.

4 Oct 2021

Antibody kinetics after natural SARS-CoV-2 infection and COVID-19 vaccination in Hispanic/Latino population

A new study addressing this issue has been published in Viruses that shows that functional neutralizing antibody tests are more relevant indicators than the presence or absence of binding antibodies.

4 Oct 2021

Difficulties of stability and storage of mRNA COVID-19 vaccines

Two researchers have collaborated to review the difficulties faced in storing and transporting these vaccines in a manner that will keep them stable.

4 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.

3 Oct 2021

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

1 Oct 2021

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

A new preprint describes promising results with a novel vaccine candidate designed to improve the breadth of neutralization.

1 Oct 2021

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

1 Oct 2021

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

A new study reported the persistence of immune responses over twelve months after natural infection.

1 Oct 2021

Similar viral load in vaccinated and unvaccinated individuals infected with SARS-CoV-2 Delta variant

Researchers evaluated Ct-values among distinct groups, namely, a) completely vaccinated and unvaccinated individuals and b) asymptomatic and symptomatic individuals at the time of testing.

1 Oct 2021

The extent to which COVID-19 vaccination reduces transmission varies with vaccine type and SARS-CoV-2 strain

Researchers from the University of Oxford have been examining the impact of vaccination on the spread of the Alpha and Delta variants through the population.

1 Oct 2021

Study finds US pediatric COVID-19 cases are higher than expected

Researchers from the CDC have investigated differences in seroprevalence across pediatric age groups to estimate an infection to case ratio.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Spike Protein News and Research

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Fully vaccinated people with prior SARS-CoV-2 infection have more memory B cells, study shows

Study looks at immunosuppressants and COVID vaccine efficacy

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Antibody kinetics after natural SARS-CoV-2 infection and COVID-19 vaccination in Hispanic/Latino population

Difficulties of stability and storage of mRNA COVID-19 vaccines

Using a new public antibody to understand SARS-CoV-2 neutralization

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

Similar viral load in vaccinated and unvaccinated individuals infected with SARS-CoV-2 Delta variant

The extent to which COVID-19 vaccination reduces transmission varies with vaccine type and SARS-CoV-2 strain

Study finds US pediatric COVID-19 cases are higher than expected

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News